NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Blue Jay Gold Corp. (TSXV: JAY) (OTCQB: JAYGF) (FSE: JAY) (“Blue Jay” or the “Company”) is pleased to announce a private placement financing with Ocean Partners UK Limited (“Ocean Partners”), an international trader of base and precious metal concentrates, for 3,333,300 units (the “Units”) at a price of $0.90 per Unit for aggregate gross proceeds to the Company of $3.0 million (the “Private Placement”). Each Unit will be comprised of one common share of Blue Jay (a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder to acquire one Common Share at a price of $1.20 for a period of one year from the closing date of the Private Placement. If, at any time, the daily volume-weighted average price of the Common Shares on the TSX Venture Exchange (“TSXV”) is at or above $1.25 for five (5) consecutive trading days, the Company may accelerate the expiry of the Warrants, in which case the Warrants will expire 30 days following the date of such acceleration.
Following closing, Ocean Partners is expected to hold approximately 6.5% of the issued and outstanding Common Shares on a non-diluted basis. Net proceeds will be used to fund exploration and study work at the Company’s Steller Gold Project (the “Steller Gold Project”), including the Company’s preliminary economic assessment planned for the first half of 2027, and for general working capital.
The Private Placement is subject to the approval of the TSXV and other customary conditions. All securities issued under the Private Placement will be subject to a statutory hold period of four months and one day from the date of issuance. No finder’s fees are payable in connection with the Private Placement. Closing is expected on or about November 5, 2026.
The securities to be offered pursuant to the Private Placement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Ocean Partners
Ocean Partners UK Limited is part of the Ocean Partners group, a leading international trader of base and precious metal concentrates. Headquartered in the United Kingdom, with offices across North America, Europe, Asia and Latin America, Ocean Partners provides marketing, logistics, blending and warehousing, and financing services to metal producers worldwide.
About Blue Jay Gold Corp.
Blue Jay is a Canadian gold exploration company focused on growing and discovering resources within established gold producing regions in Canada. The Company’s flagship asset is the 100%-owned Steller Gold Project in southern Yukon, an infrastructure-supported, past-producing mine with significant exploration upside and clear near-term catalysts. Blue Jay has also built a portfolio of projects in Ontario. With strategically located assets and a leadership team experienced in geology and capital markets, Blue Jay will advance disciplined, modern exploration programs focused on target definition, resource growth, and new discoveries in known gold-mineralized regions. For more information, please visit: www.bluejaygoldcorp.com.
Certain statements in this press release contain forward-looking information. These statements can be identified by the use of forward-looking terminology (e.g., “expect”, “estimates”, “intends”, “anticipates”, “believes”, “plans”). Forward-looking statements contained in this press release may include, but are not limited to, the completion and size of the Private Placement with Ocean Partners and the timing thereof, the gross proceeds expected to be received, the timing and receipt of TSXV approval, Ocean Partners’ anticipated ownership interest following closing, the anticipated use of proceeds, the Company’s planned exploration and study work at the Steller Gold Project, including the completion of its preliminary economic assessment and the anticipated timing thereof, the potential acceleration of the expiry of the Warrants, and the Company’s plans to advance exploration programs focused on target definition, resource growth and new discoveries.
Such forward-looking statements are based on a number of assumptions of management, including, without limitation, the Company’s ability to complete the Private Placement on the terms and within the timelines described herein, the receipt of all required approvals, including TSXV approval, the Company’s anticipated use of the proceeds received from the Private Placement, the Company’s ability to carry out its planned exploration and study work and complete its preliminary economic assessment within the anticipated timelines and the availability of sufficient financing and resources to advance the Company’s planned exploration programs.
Forward-looking information involves risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks include, without limitation, the inability of the Company to complete the Private Placement on the terms or within the timelines described herein or at all, the failure to obtain TSXV approval, the actual use of proceeds differing from the anticipated use of proceeds, the risk that the Company’s planned exploration and study work, including its preliminary economic assessment, will not be completed in the anticipated timelines or at all, the Company’s inability to advance its planned exploration programs, fluctuations in gold and silver prices, variations in grade and tonnage, the results of future financing and exploration activities, the interpretation of exploration results and other geological data, unanticipated costs and expenses and other risks identified by Blue Jay in its public securities filings. There is significant risk that the forward-looking statements will not prove to be accurate, that management’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable securities laws and regulations, Blue Jay disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
HERZLIYA, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced that it will release its earnings for the third quarter of 2026 on Wednesday, November 11, 2026, before U.S. markets open.
Nayax will hold two calls, one in English and one in Hebrew. Nayax CEO and Chairman, Yair Nechmad, will speak alongside Chief Financial Officer, Sagit Manor, and Chief Strategy Officer, Aaron Greenberg.
Conference Calls:
The conference call in English will be held at: 8:30 a.m. Eastern Time / 3:30 p.m. Israel Time / 5:30 a.m. Pacific Time.
The conference call in Hebrew will be held at: 10:00 a.m. Eastern Time / 5:00 p.m. Israel Time / 7:00 a.m. Pacific Time.
For the conference call in English, we encourage participants to pre-register using the link below. Those who pre-register will be given a unique PIN to gain immediate access to the call, bypassing the live operator. Participants may pre-register any time, including up to and after the call/webcast start time. You will immediately receive an online confirmation, an email with the dial-in number and a calendar invitation for the event.
For those who are unable to pre-register, kindly join the conference call/webcast by using one of the dial-in numbers or clicking the webcast link below.
U.S. TOLL-FREE: 1-877-737-7051 ISRAEL TOLL-FREE: 1-809-455-690 INTERNATIONAL: 1-201-689-8878
Nayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. With foundations and global leadership in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of June 30, 2026, Nayax has 13 global offices, approximately 1,250 employees, connections to more than 80 merchant acquirers and payment method integrations, and is globally recognized as a payment facilitator. Nayax’s mission is to improve our customers’ revenue potential and operational efficiency — effectively and simply. For more information, please visit www.nayax.com.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. Forward-looking statements include, but are not limited to, statements regarding our intent, belief or current expectations, such as statements in this press release regarding our financial outlook, future business prospects and the impact of recent acquisitions or partnerships published by the Company. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: our expectations regarding general market conditions, including as a result of the COVID-19 pandemic and other global economic trends; changes in consumer tastes and preferences; fluctuations in inflation, interest rate and exchange rates in the global economic environment; the availability of qualified personnel and the ability to retain such personnel; changes in commodity costs, labor, distribution and other operating costs; our ability to implement our growth strategy; changes in government regulation and tax matters; other factors that may affect our financial condition, liquidity and results of operations; general economic, political, demographic and business conditions in Israel, including the war in Israel that began on October 7, 2023 and global perspectives regarding that conflict; the success of operating initiatives, including advertising and promotional efforts and new product and concept development by us and our competitors; and other risk factors discussed under “Risk Factors” in our annual report on Form 20-F filed with the SEC on March 9, 2026 (our “Annual Report”). The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only estimates based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under “Risk Factors” in our Annual Report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Each forward-looking statement speaks only as of the date of the particular statement. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Unprecedented Efficacy in Both Refractory Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS)
PHILADELPHIA and MADRID, Oct. 26, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that one-time lifileucel monotherapy demonstrated unprecedented efficacy with deep, durable responses across two difficult-to-treat soft tissue sarcomas with limited treatment options, metastatic UPS and DDLPS, in a pilot trial presented orally at the ESMO Congress 2026 in Madrid, Spain.
Among the first eight evaluable patients, physician-assessed confirmed ORR by RECIST v1.1 was 50%. Four partial responses (2 in UPS and 2 in DDLPS) were all ongoing (at 6+, 26+, 40+, and 46+ weeks) as of the data cut-off on September 9, 2026. The eight evaluable patients had deep responses despite significant disease burden (range in baseline target sum of diameters: 39.0 to 177.6 mm), were refractory to prior lines of systemic therapy (range: 1-7), and received lifileucel that met pre-determined manufacturing specifications. The safety profile was consistent with the lifileucel treatment regimen across other indications.
Soft tissue sarcomas are rare and highly heterogeneous cancers comprising approximately 80 tumor subtypes, with an estimated incidence of 4–5 cases per 100,000 people annually in Europe and ~3.5 new diagnoses per 100,000 people in the United States each year.1, 2
“The unprecedented efficacy for one-time lifileucel in UPS and DDLPS sets a new bar for response rates with TIL therapy in refractory patients and underscores the powerful potential of our TIL platform across many solid tumor cancers,” said Brian Gastman, M.D., Executive Vice President, Translational Medicine and Research at Iovance Biotherapeutics. “UPS and DDLPS patients also experienced deepening responses over time, consistent with lifileucel’s responses in melanoma, non-small-cell lung cancer, and other solid tumors. On the heels of this pilot trial, we are rapidly enrolling the SARATOGA registrational study to support two new approvals for lifileucel. Iovance is strongly positioned to drive potential adoption in refractory UPS and DDLPS patients that are highly concentrated at academic centers that overlap with our existing commercial footprint.”
“Lifileucel showed encouraging response rates and lasting benefits in patients with UPS and DDLPS who are refractory to frontline standard of care,” said Lauren Banks, M.D., Ph.D., Sarcoma Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) and principal investigator of the pilot and SARATOGA trials of lifileucel. “This level of durability provides meaningful time for patients with refractory UPS and DDLPS suffering from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options.”
Patients with metastatic UPS and DDLPS have a devastating prognosis, with median overall survival (mOS) of less than two years and median progression-free survival (mPFS) of only 5 to 6 months after first-line chemotherapy.3 In recent clinical studies, the current second-line treatment options delivered an ORR of less than 5%, mPFS of ~2-3 months, and mOS of ~9-10 months.4–6
The U.S. Food and Drug Administration (FDA) granted fast track designation for lifileucel in advanced UPS and DDLPS in the second quarter of 2026 based on initial results from the pilot trial. Iovance is exploring lifileucel in additional metastatic soft tissue sarcomas with high unmet need as part of its clinical development program.
SARATOGA (NCT07741877) is a registrational Phase 2 clinical trial evaluating the safety and efficacy of lifileucel in patients with advanced (metastatic or unresectable) UPS or DDLPS who were refractory to at least one prior line of anthracycline-based chemotherapy. SARATOGA is now enrolling at MSKCC and other major U.S. cancer centers. The primary endpoint is ORR per RECIST v1.1 by independent review committee (IRC), with secondary endpoints including complete response rate, duration of response, disease control rate, PFS, OS, and safety and tolerability.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.
About the ESMO Congress
The ESMO Congress is one of the world’s most influential annual oncology meetings, bringing together more than 37,000 clinicians, researchers, patient advocates, and industry representatives from around the world. The ESMO Congress 2026 takes place October 23–27, 2026, at IFEMA Madrid, Spain, and features presentations of practice-changing clinical data, translational science, and educational programming across all major tumor types. For more information, visit www.esmo.org.
References
1. Gronchi A, et al. Ann Oncol. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006. 2. National Cancer Institute SEER Program. 2026 Estimates. Accessed October 13, 2026. 3. Banks L, et al. ESMO 2026. 4. Parikh RC, et al. Cancer. 2018. 5. Italiano A, et al. Ann Oncol. 2012. 6. Jones RL, et al. Ann Oncol. 2023.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the size of the addressable patient populations for, and the acceptance by the market of, our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial supply or clinical supply; the risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates; whether clinical trial results from our clinical studies and cohorts, and meetings with regulatory authorities, may support registrational studies and subsequent approvals by regulatory authorities, including the risk that our registrational trials may be delayed, may not meet their primary endpoints, or may not support approval; clinical results, whether preliminary, interim, or final, which may include efficacy and safety results, from clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior or future trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities or others; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control.
Digit humanoid robots to expand to additional GXO sites in 2027, building on industry-first Robots-as-a-Service agreement
Digit humanoid robots to expand to additional GXO sites in 2027, building on industry-first Robots-as-a-Service agreement
GREENWICH, Conn. and Salem, Ore., Oct. 26, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, and Agility Robotics, a leading humanoid robotics and physical AI company, today announced an expansion of their pioneering partnership to advance humanoid automation in logistics with deployments of Agility’s Digit humanoid robot to GXO sites in North Carolina and Tennessee.
The announcement builds on the companies’ industry-first, multi-year agreement in 2024 to deploy Agility Robotics’ Digit® humanoid robot in a live GXO warehouse environment in Flowery Branch, Georgia. The agreement was the industry’s first formal commercial deployment of humanoid robots in live operations and the first Robots-as-a-Service (RaaS) agreement for humanoid robots. Since then, Digit has moved more than 100,000 totes at the Flowery Branch facility, demonstrating its ability to perform repetitive material-handling tasks reliably in an active logistics environment.
“Innovation is most powerful when it delivers practical solutions that create value for our customers and our people,” said GXO CEO Patrick Kelleher. “Our partnership with Agility Robotics has been defined by a shared commitment to turning emerging technologies into real-world operational advantage. Together, we’ve helped pioneer the use of humanoid robotics in the warehouse and this expansion reflects our confidence in the technology’s ability to create measurable value for our customers and a better working environment for our teams.”
“GXO was the first customer to put Digit to work in live operations under a commercial agreement, and expanding to additional sites is the clearest signal that the value is real,” said Peggy Johnson, CEO of Agility Robotics. “Customers are moving beyond asking whether humanoid robots can work to deciding where they can scale them. Years of experience performing real work in GXO’s operations have shaped how we build, deploy and support Digit, and we’re focused on disciplined execution as we grow this partnership.”
From Industry-First to Multi-Site Expansion
GXO and Agility began working together with a proof-of-concept pilot in late 2023 at GXO’s Flowery Branch site. In June 2024, the companies signed a multi-year RaaS agreement under which GXO deployed Digit robots and Agility Arc, Agility’s cloud-based platform for managing robot fleets and integrating them into customer operations. At Flowery Branch, Digit has worked alongside existing automation to move totes and place them onto conveyors.
Under the expanded agreement, Digit will support e-commerce fulfillment at GXO’s Statesville and Lebanon sites, taking on highly repetitive material-handling tasks. Deployments are expected to begin in early 2027 using Digit 4 and will migrate to Digit 5 when it becomes commercially available.
The expansion reflects GXO’s long-standing approach to advancing warehouse automation through practical implementation at scale. As an industry leader in advanced automation and physical AI, GXO partners with leading technology developers to test, refine and deploy emerging solutions in live operating environments. The expanded partnership underscores GXO’s and Agility’s shared commitment to accelerating innovation through real-world application and continuous learning.
Building the Infrastructure for Commercial Scale
Across its commercial operations and customer programs, Digit has accumulated more than 65,000 hours of real-world operation. That experience has informed the development of Digit 5, Agility’s next-generation robot unveiled on September 15, 2026, which is designed for cooperatively safe work in close proximity to people and will address a broader range of industrial workflows.
To support broader commercial adoption, Agility has invested in the infrastructure needed to manufacture, deploy and support humanoid robots at scale, including RoboFab, its 70,000-square-foot manufacturing facility in Salem, Oregon, designed for annual production capacity of up to 10,000 robots; Agility Arc; and expanded software, deployment and service capabilities, including its recently announced Pittsburgh expansion.
As previously announced, Agility is preparing to become a public company through its business combination with Churchill Capital Corp XI (Nasdaq: CCXI). The business combination is expected to close in the fourth quarter of 2026, after which the combined company will operate as Agility Robotics and is expected to trade on Nasdaq under the ticker symbol “AGLT.”
About GXO GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.
About Agility Robotics Headquartered in Salem, Oregon, with offices in Pittsburgh, Pennsylvania and Fremont, California, Agility Robotics’ mission is to build robot partners that augment the human workforce. Agility’s groundbreaking general-purpose humanoid robot, Digit, is the first multi-purpose, human-centric robot that is Made for Work® and commercially deployed today. With more than 65,000 hours of real-world operation combined with industry-leading safety standards, we’re pioneering a new era of automation that enhances human potential. To learn more, visit agilityrobotics.com.
Agility, the Agility logo, Digit, Agility Arc, RoboFab, and Made for Work are trademarks of Agility Robotics, Inc. All rights reserved. Third-party trademarks are the property of their respective owners.
About Churchill Capital Corp XI Churchill Capital Corp XI (“Churchill XI”) is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.
Additional Information About the Proposed Transaction and Where to Find It
The proposed transaction will be submitted to shareholders of Churchill XI for their consideration. Churchill XI and Agility Robotics have jointly filed a registration statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”), which was declared effective by the SEC on October 13, 2026, and which includes a definitive proxy statement/prospectus. The definitive proxy statement/prospectus and other relevant documents have been distributed to Company stockholders and Churchill XI shareholders as of September 14, 2026, the record date established for voting on the proposed transaction, in connection with Churchill XI’s solicitation of proxies for the vote by Churchill XI’s shareholders in connection with the proposed transaction and other matters described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Company stockholders in connection with the completion of the proposed transaction. Before making any voting or investment decision, Churchill XI and Agility stockholders and other interested persons are advised to read the definitive proxy statement/prospectus, as well as other documents filed with the SEC by Churchill XI in connection with the proposed transaction, as these documents contain important information about Churchill XI, the Company and the proposed transaction. Shareholders may obtain a copy of the definitive proxy statement/prospectus as well as other documents filed by Churchill XI with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to Churchill Capital Corp XI, 640 Fifth Avenue, 14th Floor, New York, NY 10019.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the federal securities laws regarding Agility and Churchill XI. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should” and “would,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of any of these words or similar expressions does not mean that a statement is not forward-looking. These forward-looking statements are based on Agility’s and Churchill XI’s current expectations and projections. These statements include statements relating to, without limitation: Agility’s estimates of customer adoption rates, market acceptance and usage patterns; the expected expansion of Agility’s partnership with GXO, including the anticipated deployment of Digit at GXO’s Statesville and Lebanon sites beginning in early 2027 and the expected migration of those deployments to Digit 5 when it becomes commercially available; the timing and success of the Company’s future development plans; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products and services; expectations regarding the Company’s ability to attract, retain and expand its customer base; the Company’s expectations concerning relationships with strategic partners, suppliers, regulatory bodies and other third parties; Agility’s ability to convert paid customer programs and pilots into larger robot orders, deployments and multi-year commitments; Agility’s ability to develop, validate and deploy new Digit skills and capabilities, including the expected capabilities of Digit 5 and its ability to address a broader range of industrial workflows; Agility’s ability to scale manufacturing, including at RoboFab, commercial deployments and service infrastructure to support existing and future customers; Agility’s preparation to operate as a public company; and Agility’s ability to consummate the proposed business combination with Churchill XI, including the anticipated timing of closing and the expected listing of the combined company’s securities on Nasdaq.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company and Churchill XI.
These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the Company’s, Churchill XI’s or the combined company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that the Company is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; the Company’s historical net losses and limited operating history; the Company’s expectations regarding future financial performance, capital requirements and unit economics; the Company’s use and reporting of business and operational metrics; the Company’s competitive landscape; the Company’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; the Company’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; the Company’s reliance on strategic partners and other third parties; the Company’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Churchill XI’s securities; the failure by the parties to satisfy the conditions to consummation of the proposed transaction, including the approval of Churchill XI’s shareholders; the possibility that required regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of Churchill XI could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the level of redemptions of Churchill XI’s public shareholders; the ability of the Company to grow and manage growth, maintain relationships with customers and retain its management and key employees; costs related to the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against the Company or Churchill XI; failure to realize the anticipated benefits of the proposed transaction; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of Churchill XI or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in Churchill XI’s filings with the SEC. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by the Company, Churchill XI or the combined company resulting from the proposed transaction with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of the Company’s and Churchill XI’s management as of the date of this press release; subsequent events and developments may cause their assessments to change. While the Company and Churchill XI may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. Accordingly, undue reliance should not be placed upon these statements.
In addition, statements that “we believe” and similar statements reflect the Company’s and Churchill XI’s beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the Company’s and Churchill XI’s statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
An investment in Churchill XI is not an investment in any of Churchill XI’s founders’ or sponsors’ past investments, companies or affiliated funds. The historical results of those investments are not indicative of future performance of Churchill XI, which may differ materially from the performance of Churchill XI’s founders’ or sponsors’ past investments.
No Offer or Solicitation
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
Transformation Efforts Continue to Drive Growth and Profitability
Company Raises Full-Year Guidance for Third Consecutive Quarter
Verizon and Amazon Web Services (AWS) Expand Strategic Partnership with Landmark $2B+ AI Infrastructure Deal
3Q26 Key Highlights:
Delivered 406,000 postpaid phone net additions, a more than 820.0 percent increase year-over-year, representing the strongest third-quarter performance in five years.
Added 137,000 postpaid net accounts, marking the company’s best performance in over a decade.
Acquired nearly 1.7 million mobility and broadband subscribers in the first nine months of 2026, compared to 879,000 in the first nine months of 2025.
Mobility and broadband service revenue of $23.5 billion grew 2.9 percent year-over-year, up sequentially and forecast to grow approximately 4.0 percent in fourth-quarter 2026.
Cash flow from operating activities was $11.5 billion for the quarter, representing an increase of 2.2 percent year-over-year. This supported free cash flow¹ of $7.8 billion, up 12.1 percent year-over-year.
Sharp focus on operational efficiency resulted in strong consolidated net income performance of $5.3 billion, up 5.2 percent year-over-year. This drove consolidated Adjusted EBITDA1 of $13.8 billion, up 8.0 percent year-over-year, which represents the highest quarterly result the company has ever reported.
Earnings per share (EPS) was $1.25, up 6.8 percent year-over-year, driving Adjusted EPS¹ of $1.31, up 8.3 percent year-over-year.
Raised full-year 2026 guidance for key metrics for the third consecutive quarter, including for postpaid phone net additions, Adjusted EPS¹, and free cash flow¹.
Signed an agreement valued at $2.0+ billion with AWS that establishes a commercial framework to scale distributed compute and meet the real-time demands of agentic and generative AI workloads.
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) today announced third-quarter 2026 results that set new company benchmarks. This performance highlights the momentum behind its multi-year transformation. Verizon delivered its strongest third-quarter postpaid phone net adds in five years, and its best quarterly net account growth in over a decade, alongside lower year-over-year churn. With these strong results and the underlying performance of the business, Verizon raised its full-year guidance for the third consecutive quarter.
“Verizon delivered another record-breaking quarter. One year into our transformation, Verizon is fundamentally stronger — operationally, financially, and competitively,” said Dan Schulman, Verizon CEO. “By prioritizing customer-first offerings like Simplicity and our expanded loyalty program over heavy subsidies, we are winning loyal, high-value customers while expanding margins, reducing churn, and generating strong sustained cash flow. At the same time, technology leaders are choosing our fiber network to power the next generation of AI infrastructure. We are continuing to raise the bar and we are only one year into a multi-year growth story.”
3Q 2026 Highlights
Mobility and Broadband
Mobility and broadband service revenue reached approximately $23.5 billion, representing a 2.9 percent increase year-over-year, continuing a sequential improvement from 2.8 percent in second-quarter 2026 and 1.6 percent in first-quarter 2026.
Reported total postpaid phone net additions of 406,000 in third-quarter 2026, a more than 820.0 percent increase year-over-year, marking the strongest third-quarter performance in five years.
Delivered 137,000 postpaid net account additions, marking the best performance in over a decade.
Overall postpaid phone churn improved 4 bps year-over-year to 0.94 percent, with Consumer postpaid phone churn also improving 4 bps to 0.87 percent. Promotional cost of acquisition decreased 41 percent year-over-year, and promotional cost of retention improved by 30 percent year-over-year.
Delivered 314,000 broadband net additions in third-quarter 2026. This includes total fixed wireless access net additions of 159,000 and 155,000 fiber broadband net additions.
Verizon now maintains 17.4 million total broadband connections, with more than half of new fiber customers choosing 1-gigabit-plus download speeds.
The company continues to anticipate total fiber passings to exceed 32 million by year-end, remaining on track toward a target of 40 to 50 million fiber passings over the medium term.
Consolidated Financial Results
Total operating revenue was $34.3 billion, up 1.5 percent year-over-year. Mobility and broadband service revenue growth of 2.9 percent was offset by a 9.0 percent year-over-year decline in equipment revenue. This decline resulted primarily from significantly lower upgrade volumes, as the average time customers keep their mobile devices continues to increase, and the company’s strategic decision to reduce spending on device subsidies. It is another demonstration of Verizon’s more disciplined approach as the company structurally evolves its business model.
In third-quarter 2026, Verizon had strong consolidated net income of $5.3 billion, a 5.2 percent increase year-over-year, and strong consolidated net income margin of 15.5 percent compared to 14.9 percent in third-quarter 2025.
Consolidated Adjusted EBITDA1 grew 8.0 percent year-over-year to $13.8 billion, the highest the company ever reported.
Consolidated Adjusted EBITDA margin1 grew from 37.8 to 40.2 percent year-over-year, the highest the company ever reported.
EPS was $1.25 in third-quarter 2026, a 6.8 percent increase compared to $1.17 in third-quarter 2025; Adjusted EPS1, excluding special items, was $1.31 in third-quarter 2026, an 8.3 percent increase compared to $1.21 in third-quarter 2025.
In third-quarter 2026, cash flow from operations was $11.5 billion, up 2.2 percent year-over-year. Free cash flow1 was $7.8 billion in third-quarter 2026, up 12.1 percent year-over-year.
Cash flow from operations was $29.9 billion for the first nine months of the year, compared to $28.0 billion for the same period in 2025, representing a growth rate of nearly 7.0 percent. Free cash flow1 for the first nine months of the year was $18.0 billion, up 14.3 percent year-over-year.
Capital expenditures were $11.9 billion for the first nine months of the year, reflecting sustained, disciplined investment to maintain network excellence and capture high-return expansion across mobility and broadband.
Verizon’s total unsecured debt as of the end of third-quarter 2026 was $136.1 billion, compared to $136.5 billion at the end of second-quarter 2026. The company’s net unsecured debt1 at the end of third-quarter 2026 was $123.7 billion compared to $128.7 billion at the end of second-quarter 2026. At the end of third-quarter 2026, Verizon’s ratio of unsecured debt to consolidated net income (LTM) was 8.1 times and its net unsecured debt to consolidated Adjusted EBITDA ratio1 was 2.3 times.
In the first nine months of the year, Verizon returned $12.8 billion of capital to shareholders, up 49.0 percent year-over-year. This includes dividend payments of $8.8 billion and share repurchases of $4.0 billion. The company continues to expect to repurchase up to $4.5 billion for the full year.
Outlook and Guidance Verizon does not provide a reconciliation for certain of the following adjusted (non-GAAP) forecasts because it cannot, without unreasonable effort, predict the special items that could arise, and the company is unable to address the probable significance of the unavailable information.
Given the strong third-quarter 2026 performance and continued operational momentum, Verizon is raising its full-year 2026 guidance as follows:
Postpaid phone net additions: 1.1 million to 1.2 million, up from upper half of 750,000 to 1.0 million, representing an increase of more than three times compared to 2025.
Adjusted EPS¹: $5.04 to $5.06, or 7.0 to 7.5 percent growth year-over-year, up from 6.0 to 7.0 percent.
Cash flow from operations: 3.5 to 5.0 percent growth year-over-year, up from 2.0 to 4.0 percent.
Free cash flow¹: expected to approach 12.0 percent growth year-over-year, up from 9.0 to 10.0 percent.
Mobility and broadband service revenue: upper half of annual guidance of 2.5 to 3.0 percent growth, with approximately 4.0 percent growth in fourth-quarter 2026.
In addition, for 2026, Verizon continues to expect the following:
Capital expenditures: $16.0 billion to $16.5 billion, inclusive of success-based investments for AI Connect.
1 Non-GAAP financial measure. See the accompanying schedules and www.verizon.com/about/investors for reconciliations of non-GAAP financial measures cited in this document to most directly comparable financial measures under generally accepted accounting principles (GAAP).
Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving countries worldwide and nearly all of the Fortune 500, Verizon generated revenues of $138.2 billion in 2025. Verizon’s world-class team never stops innovating to meet customers where they are today and equip them for the needs of tomorrow. For more, visit verizon.com or find a retail location at verizon.com/stores.
VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/about/news. For images and logos, visit verizon.com/about/news/media-resources. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.
Forward-looking statements
In this communication we have made forward-looking statements. These statements are based on our estimates and assumptions and are subject to risks and uncertainties. Forward-looking statements include the information concerning our possible or assumed future results of operations. Forward-looking statements also include those preceded or followed by the words “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “forecasts,” “hopes,” “intends,” “plans,” “targets,” “will” or similar expressions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The following important factors, along with those discussed in our filings with the Securities and Exchange Commission (the “SEC”), could affect future results and could cause those results to differ materially from those expressed in the forward-looking statements: the effects of competition in the markets in which we operate, including the inability to successfully respond to competitive factors such as prices, promotional incentives, network performance and quality, and evolving consumer preferences; failure to take advantage of, or respond to competitors’ use of, developments in technology, including artificial intelligence, and address changes in consumer demand; the inability to implement our business strategy; adverse conditions in the U.S. and international economies, including inflation and changing interest rates in the markets in which we operate; changes to international trade and tariff policies and related economic and other impacts; cyberattacks impacting our networks or systems and any resulting financial or reputational impact; our ability to implement business transformation initiatives and achieve their anticipated benefits; system failures and disruptions to our networks and operations and any resulting financial, reputational or business impact; disruption of our key suppliers’ or vendors’ provisioning of products or services, including as a result of geopolitical factors, public health crises, natural disasters or extreme weather conditions; material adverse changes in labor matters and any resulting financial or operational impact; damage to our reputation or brands; changes in the regulatory environment in which we operate, including any increase in restrictions on our ability to operate our networks or businesses; allegations regarding the release of hazardous materials or pollutants into the environment from our, or our predecessors’, network assets and any related government investigations, regulatory developments, litigation, penalties and other liability, remediation and compliance costs, operational impacts or reputational damage; significant amount of outstanding debt; significant litigation and any resulting material expenses incurred in defending against lawsuits or paying awards or settlements; an adverse change in the ratings afforded our debt securities by nationally accredited ratings organizations or adverse conditions in the credit markets affecting the cost, including interest rates, and/or availability of further financing; significant increases in benefit plan costs or lower investment returns on plan assets; changes in tax laws or regulations, or in their interpretation, or challenges to our tax positions, resulting in additional tax expense or liabilities; changes in accounting assumptions that regulatory agencies, including the SEC, may require or that result from changes in the accounting rules or their application, which could result in an impact on earnings; our ability to return capital to shareholders, including the amount, timing, and effect of share repurchases and dividends; and risks associated with mergers, acquisitions, divestitures and other strategic transactions, including our ability to obtain cost savings and other synergies and anticipated benefits of completed transactions within the expected time period or at all.
Consolidated EBITDA and Consolidated Adjusted EBITDA
(dollars in millions)
Unaudited
3 Mos. Ended 9/30/26
3 Mos. Ended 6/30/26
3 Mos. Ended 3/31/26
3 Mos. Ended 12/31/25
3 Mos. Ended 9/30/25
3 Mos. Ended 6/30/25
3 Mos. Ended 3/31/25
Consolidated Net Income
$
5,320
$
3,949
$
5,146
$
2,448
$
5,056
$
5,121
$
4,983
Add:
Provision for income taxes
1,497
1,325
1,638
615
1,471
1,488
1,490
Interest expense(1)
1,950
1,985
1,940
1,759
1,664
1,639
1,632
Depreciation and amortization expense(2)
5,095
5,008
4,892
4,519
4,618
4,635
4,577
Consolidated EBITDA
$
13,862
$
12,267
$
13,616
$
9,341
$
12,809
$
12,883
$
12,682
Add/(subtract):
Other (income) expense, net(3)
$
(120
)
$
(36
)
$
(477
)
$
185
$
(92
)
$
(79
)
$
(121
)
Equity in (earnings) losses of unconsolidated businesses
3
(44
)
(5
)
(3
)
6
3
(6
)
Severance charges
—
397
—
1,715
—
—
—
Acquisition and integration related charges
57
135
261
39
52
—
—
Asset and business rationalization
—
258
—
583
—
—
—
Loss on disposition of business
—
746
—
—
—
—
—
(60
)
1,456
(221
)
2,519
(34
)
(76
)
(127
)
Consolidated Adjusted EBITDA
$
13,802
$
13,723
$
13,395
$
11,860
$
12,775
$
12,807
$
12,555
Consolidated Operating Revenues
$
34,313
$
33,821
Consolidated Net Income Margin
15.5
%
14.9
%
Consolidated Adjusted EBITDA Margin
40.2
%
37.8
%
Consolidated Adjusted EBITDA – Year over year change %
8.0
%
Footnotes:
(1) Includes a portion of the Acquisition and integration related charges, where applicable.
(2) Includes Amortization of acquisition-related intangible assets.
(3) Includes Pension and benefits remeasurement adjustments, where applicable.
Consolidated EBITDA and Consolidated Adjusted EBITDA (LTM)
(dollars in millions)
Unaudited
12 Mos. Ended 9/30/26
12 Mos. Ended 12/31/25
Consolidated Net Income
$
16,863
$
17,608
Add:
Provision for income taxes
5,075
5,064
Interest expense(1)
7,634
6,694
Depreciation and amortization expense(2)
19,514
18,349
Consolidated EBITDA
$
49,086
$
47,715
Add/(subtract):
Other income, net(3)
$
(448
)
$
(107
)
Equity in (earnings) losses of unconsolidated businesses
(49
)
—
Severance charges
2,112
1,715
Acquisition and integration related charges
492
91
Asset and business rationalization
841
583
Loss on disposition of business
746
—
3,694
2,282
Consolidated Adjusted EBITDA
$
52,780
$
49,997
Footnotes:
(1) Includes a portion of the Acquisition and integration related charges, where applicable.
(2) Includes Amortization of acquisition-related intangible assets.
(3) Includes Pension and benefits remeasurement adjustments, where applicable.
Net Unsecured Debt and Net Unsecured Debt to Consolidated Adjusted EBITDA Ratio
(dollars in millions)
Unaudited
9/30/26
6/30/26
12/31/25
Debt maturing within one year
$
23,889
$
21,783
$
18,618
Long-term debt
142,344
143,448
139,532
Total Debt
166,233
165,231
158,150
Less: Secured debt
30,138
28,760
27,067
Unsecured Debt
136,095
136,471
131,083
Less: Equity credit for junior subordinated notes(1)
7,879
6,037
1,982
Less: Cash and cash equivalents
4,495
1,752
19,048
Net Unsecured Debt
$
123,721
$
128,682
$
110,053
Consolidated Net Income (LTM)
$
16,863
$
17,608
Unsecured Debt to Consolidated Net Income Ratio
8.1x
7.4x
Consolidated Adjusted EBITDA (LTM)
$
52,780
$
49,997
Net Unsecured Debt to Consolidated Adjusted EBITDA Ratio
2.3x
2.2x
Footnote:
(1) Represents a fifty percent equity credit related to junior subordinated notes outstanding.
Adjusted Earnings per Common Share (Adjusted EPS)
(dollars in millions, except per share amounts)
Unaudited
3 Mos. Ended 9/30/26
3 Mos. Ended 9/30/25
Pre-tax
Tax
After-Tax
Pre-tax
Tax
After-Tax
EPS
$
1.25
$
1.17
Amortization of acquisition-related intangible assets
$
289
$
(72
)
$
217
0.05
$
189
$
(48
)
$
141
0.03
Acquisition and integration related charges
57
(2
)
55
0.01
52
—
52
0.01
$
346
$
(74
)
$
272
$
0.07
$
241
$
(48
)
$
193
$
0.05
Adjusted EPS
$
1.31
$
1.21
Year over year change %
8.3
%
Footnote:
Adjusted EPS may not add due to rounding.
Free Cash Flow
(dollars in millions)
Unaudited
3 Mos. Ended 9/30/26
3 Mos. Ended 9/30/25
9 Mos. Ended 9/30/26
9 Mos. Ended 9/30/25
Net Cash Provided by Operating Activities
$
11,517
$
11,266
$
29,936
$
28,023
Capital expenditures (including capitalized software)
(3,716
)
(4,310
)
(11,926
)
(12,263
)
Free Cash Flow
$
7,801
$
6,956
$
18,010
$
15,760
Year over year change %
12.1
%
14.3
%
Free Cash Flow
(dollars in millions)
Unaudited
12 Mos. Ended 12/31/25
12 Mos. Ended 12/31/24
12 Mos. Ended 12/31/23
12 Mos. Ended 12/31/22
12 Mos. Ended 12/31/21
12 Mos. Ended 12/31/20
Net Cash Provided by Operating Activities
$
37,137
$
36,912
$
37,475
$
37,141
$
39,539
$
41,768
Capital expenditures (including capitalized software)
(17,011
)
(17,090
)
(18,767
)
(23,087
)
(20,286
)
(18,192
)
Free Cash Flow
$
20,126
$
19,822
$
18,708
$
14,054
$
19,253
$
23,576
Free Cash Flow Forecast for Full Year 2026
(dollars in millions)
Updated
Previous
Unaudited
Forecast
Forecast
Net Cash Provided by Operating Activities Forecast
$
38,440 – 39,040
$
37,940 – 38,640
Capital expenditures forecast (including capitalized software)
(16,000 – 16,500)
(16,000 – 16,500)
Free Cash Flow Forecast
$
22,440 – 22,540
$
21,940 – 22,140
Net Cash Provided by Operating Activities Growth Forecast %
3.5 % – 5.1 %
2.2 % – 4.0 %
Free Cash Flow Growth Forecast %
11.5 % – 12.0 %
9.0 % – 10.0 %
Non-GAAP Reconciliations – Segments
Segment EBITDA and Segment EBITDA Margin
Consumer
(dollars in millions)
Unaudited
3 Mos. Ended 9/30/26
3 Mos. Ended 9/30/25
9 Mos. Ended 9/30/26
9 Mos. Ended 9/30/25
Operating Income
$
8,093
$
7,664
$
23,839
$
22,731
Add: Depreciation and amortization expense
3,872
3,568
11,389
10,693
Segment EBITDA
$
11,965
$
11,232
$
35,228
$
33,424
Year over year change %
6.5
%
5.4
%
Total operating revenues
$
26,432
$
26,105
$
79,127
$
78,371
Operating Income Margin
30.6
%
29.4
%
30.1
%
29.0
%
Segment EBITDA Margin
45.3
%
43.0
%
44.5
%
42.6
%
Business
(dollars in millions)
Unaudited
3 Mos. Ended 9/30/26
3 Mos. Ended 9/30/25
9 Mos. Ended 9/30/26
9 Mos. Ended 9/30/25
Operating Income
$
855
$
716
$
2,802
$
2,186
Add: Depreciation and amortization expense
1,086
1,002
3,226
2,989
Segment EBITDA
$
1,941
$
1,718
$
6,028
$
5,175
Year over year change %
13.0
%
16.5
%
Total operating revenues
$
7,023
$
6,843
$
21,308
$
20,818
Operating Income Margin
12.2
%
10.5
%
13.1
%
10.5
%
Segment EBITDA Margin
27.6
%
25.1
%
28.3
%
24.9
%
Footnote:
In the second quarter of 2026, the net assets representing Verizon’s international wireline connectivity and managed network services business were classified as assets and liabilities held for sale and moved from the Business segment to Corporate and other. Where applicable, historical segment results have been reclassified to conform to the current period presentation.
FORT WORTH, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it plans to release its 2026 third quarter financial and operating results after the close of trading on Monday, November 9, 2026.
HighPeak Energy will host a conference call and webcast on Tuesday, November 10, 2026 at 10:00 a.m. Central Time for investors and analysts to discuss its 2026 third quarter financial results and operational highlights. Participants may register for the call here. Access to the live audio-only webcast and replay of the earnings release conference call may be found here. A live broadcast of the earnings conference call will also be available on HighPeak Energy’s website at www.highpeakenergy.com under the “Investors” section of the website.
About HighPeak Energy, Inc.
HighPeak Energy is a publicly traded independent oil and natural gas company, headquartered in Fort Worth, Texas, focused on the acquisition, development, exploration and exploitation of oil and natural gas reserves in the Midland Basin in West Texas. For more information, please visit our website at www.highpeakenergy.com.
TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today provided an update on construction of its cobalt sulfate refinery in Temiskaming Shores, Ontario, a strategic critical minerals processing facility supported by the governments of the United States, Canada and Ontario. The site workforce has grown to 130 people, up from approximately 60 at the time of the Company’s August update. Construction is advancing across all process areas, and the project continues to track within its US$73 million budget.
Since the August update, work has moved from foundations and steel erection to equipment installation, building enclosure, and electrical and instrumentation installation:
Safety: Construction is proceeding with zero lost-time incidents through a period of heavier site activity, a growing number of new workers and work areas that change as construction progresses.
Existing Refinery: Flushing and removal of redundant brownfield equipment and piping within the refinery is largely complete, and partition walls for the motor control centre room are complete.
Solvent Extraction Building: Interior structural steel installation is complete, allowing piping and electrical work to progress. Alignment of the modules is complete, and fiberglass-reinforced plastic (FRP) lamination of the process equipment has commenced.
Crystallizer Building: Mechanical equipment within the crystallization circuit is installed. Process ductwork is on site and being staged for installation, off-site pipe fabrication is well underway, and the building enclosure, including wall cladding and roofing, is nearing completion.
Product Silo: The silo building has been erected, and roof decking and cladding are being installed to enclose the dry product storage, handling and final packaging areas.
Electrical and Instrumentation: Installation of interior and exterior cable trays within the refinery is nearing completion, and the main power cable from the refinery to the solvent extraction electrical house is complete.
Tailings: Phase II construction of the tailings storage facility is underway, with civil works approximately 40% complete.
Schedule pressure has emerged from the projected timing for fabrication and installation of FRP process piping in the solvent extraction area. Following the recent award of the FRP contract, Electra is evaluating measures to accelerate this work. With major permits in hand, major long-lead equipment largely on site and the remaining process areas advancing, the Company expects any schedule adjustment, if required, to be modest.
“North America needs a domestic source of battery-grade cobalt, and this refinery is becoming that source,” said Trent Mell, CEO. “The progress to date reflects a focused team and a strong group of contractors working safely and moving this project toward commissioning. With feed secured, key offtake committed and strategic partners alongside us, we are confident in the path ahead.”
Electra is executing the project through a series of construction packages tied to the refinery’s principal process areas. The major construction contractors by work area are WB Melback Corporation (solvent extraction), Pro Pipe Construction Ltd., a subsidiary of Dalcon Construction (crystallizer), Kilmarnock Enterprises (existing refinery), MECC (electrical) and Pedersen Construction (tailings storage facility). Electra has also executed an agreement with FRP Systems Ltd. of Thunder Bay, Ontario, for the FRP process piping. Remaining engineering activity is largely focused on field-driven changes and construction support.
“Every area of the site is active, and the focus is moving from infrastructure to equipment,” said Paolo Toscano, Vice President, Projects & Engineering. “Mechanical equipment is now installed in the crystallizer, the solvent extraction area is taking shape, and our commissioning team is already validating instruments and developing the laboratory methods we will use to certify product. We are building this refinery safely and with the operating team that will run it.”
Alongside the skilled trades on site, Electra’s owner’s team continues to grow, with recent additions in health, safety and environment, maintenance and the laboratory.
The operating team, led by General Manager and Commissioning Leader Garzon Duenas, is developing the commissioning execution plan and operational readiness program, supported by a newly appointed Commissioning Lead. Metso has been engaged to provide site advisory services through mechanical completion and commissioning, and a tender for commissioning services is being prepared. Readiness work is also advancing on site: the laboratory has completed analytical method development for battery-grade cobalt sulfate, Rockwell Automation control system work is progressing, and instrument validation is underway.
On the commercial side, the Company’s agreement with Glencore AG, announced August 20, 2026, secures 100% of the cobalt hydroxide feedstock required for commissioning and ramp-up through 2027 and provides long-term supply through 2031. Approximately 60% of planned cobalt sulfate production through 2029 is committed to LG Energy Solution under a binding term sheet signed in March 2026. The term sheet with WMC Group AG, announced October 13, 2026, contemplates a five-year working capital and commercial partnership covering feedstock finance, logistics and marketing. WMC has committed to make an investment in Electra upon execution of definitive agreements. Douglas Geniti, based in New York, is supporting customer development, including defense and industrial offtake.
Electra’s refinery is a permitted brownfield facility designed to process approximately 18,000 tonnes of cobalt hydroxide feed per year to produce 5,120 tonnes per year of contained cobalt in battery-grade cobalt sulfate for North American lithium-ion battery, energy storage, defence and industrial markets.
About Electra Battery Materials
Electra is a leader in advancing North America’s critical minerals supply chain for lithium-ion batteries. The Company’s primary focus is constructing North America’s first battery-grade cobalt sulfate refinery, as part of a phased strategy to onshore critical minerals refining and reduce reliance on foreign supply chains. In addition to the refinery, Electra holds a significant land package in Idaho’s Cobalt Belt, including its Iron Creek project and surrounding properties, positioning the Company as a potential cornerstone for North American cobalt and copper production.
Electra is also advancing black mass recycling opportunities to recover critical materials from end-of-life batteries, while continuing to evaluate growth opportunities in nickel refining and other downstream battery materials. For more information, please visit www.ElectraBMC.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, including statements regarding the approved construction budget and its sufficiency; project milestones such as contract awards, site mobilization, commissioning, mechanical completion, commercial production and ramp-up; the targeted timing of mechanical completion and related schedule mitigation measures; the commissioning execution plan, operational readiness program and the anticipated commissioning services tender; anticipated workforce and hiring levels; the execution of definitive agreements with contractors and suppliers, including under the letter of intent with FRP Systems Ltd.; targeted throughput and production volumes; availability of equipment, reagents, feedstock and other inputs; commercial arrangements, including the proposed partnership with, and investment by, WMC Group AG; and the availability and timing of governmental or other financial support. Generally, forward-looking statements can be identified by the use of terminology such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved” or similar expressions and are based on current assumptions and expectations. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, and opportunities to differ materially from those implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are set forth in the management discussion and analysis and other disclosures of risk factors for Electra Battery Materials Corporation, at www.sedarplus.com and on EDGAR at www.sec.gov. Although Electra Battery Materials Corporation believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Electra Battery Materials Corporation disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Aoxiangyu 819, Aoyu 966, and Aoyu 288 delivered yield gains of 6.0% to 8.6% over control varieties in two-year national regional trials; 30-day public notice period runs through November 22, 2026
BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) — Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”), a leading Chinese agricultural technology company, today announced that three of its corn varieties, Aoxiangyu 819, Aoyu 966, and Aoyu 288, have passed the preliminary review of the 13th Session of the Fifth National Crop Variety Approval Committee of China. The three varieties are bred for the Huang-Huai-Hai Summer Corn Region, one of China’s major corn-producing areas, and each outyielded its designated control variety in both the two-year national regional trials and the 2025 production trials.
The Committee published its preliminary review results on October 22, 2026, finding that the three varieties meet China’s national standards for corn variety approval. Under China’s Measures for the Approval of Major Crop Varieties, preliminary review is followed by a 30-day public notice period, which runs from October 22 through November 22, 2026. Following completion of the applicable approval procedures, the varieties are suitable for cultivation in major areas of the Huang-Huai-Hai Summer Corn Region, including parts of Henan, Shandong, Hebei, Shaanxi, Shanxi, Jiangsu, Anhui, and Hubei provinces.
Mr. Weibin Yan, Chief Executive Officer of Origin Agritech, commented: “The preliminary review of these three varieties is an important milestone for Origin’s breeding and commercialization pipeline. Their consistent yield performance across regional and production trials demonstrates the strength of our breeding capabilities and provides additional products for our expansion in the Huang-Huai-Hai region.”
“As we enter the Strong Growth Stage of our development plan, expanding our variety portfolio remains a key priority. Combined with our growing regional sales network and technology platform, these new varieties strengthen our foundation for sustainable growth and our long-term goal of becoming one of China’s leading corn seed companies.”
Yield Performance in National Trials
All three varieties demonstrated consistent yield advantages over the designated control varieties in China’s national, regional, and production trials. One mu is one-fifteenth of a hectare, so a yield of 697.9 kilograms per mu equals roughly 10.5 metric tons per hectare, or about 167 bushels per acre.
Aoxiangyu 819, developed by Beijing Origin Agritech Seed Co., Ltd. and Hainan Aoyu Biotechnology Co., Ltd., achieved an average yield of 697.9 kilograms per mu over two years of regional trials, 8.6% above the control variety. In the 2025 production trial, Aoxiangyu 819 achieved an average yield of 662 kilograms per mu, 5.9% above the control.
Aoyu 966, also developed by Beijing Origin Agritech Seed Co., Ltd. and Hainan Aoyu Biotechnology Co., Ltd., achieved an average yield of 696.8 kilograms per mu over two years of regional trials, 6.9% above the control. In the 2025 production trial, the variety achieved an average yield of 668 kilograms per mu, 7.0% above the control.
Aoyu 288, developed by Beijing Origin Agritech Seed Co., Ltd., achieved an average yield of 670.2 kilograms per mu over two years of regional trials, 6.0% above the control. In its production trial, Aoyu 288 achieved an average yield of 694 kilograms per mu, 6.2% above the control.
The three varieties also demonstrated competitive agronomic characteristics, including maturity periods of approximately 103 days and 100-kernel weights ranging from 34.7 grams to 35.6 grams.
Expanding Origin’s Commercial Variety Pipeline
The Huang-Huai-Hai region is a strategically important corn-growing area in China. The addition of three varieties with demonstrated yield advantages further expands Origin’s product portfolio and provides additional opportunities to strengthen its presence in the region.
The new varieties complement Origin’s existing commercial portfolio, including Zhongdan 6202 and Bangzhongbang 889, as the Company continues to introduce new products across its major markets.
Advancing Breeding Innovation and Commercialization
The preliminary review of the three varieties represents another milestone in Origin’s breeding and commercialization program. The Company continues to strengthen its breeding capabilities through a combination of proprietary germplasm, conventional breeding, biotechnology, gene-editing technologies, and AI-assisted breeding tools.
With an expanding portfolio of commercial and pipeline varieties, Origin is focused on improving its ability to deliver high-performing corn varieties to farmers while expanding its geographic coverage across China’s major corn-producing regions.
About Origin Agritech Limited
Origin Agritech Limited, founded in 1997 and headquartered at the Origin R&D Center in Songzhuang, Tongzhou, Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnology, Origin Agritech’s phytase corn was the first transgenic corn to receive a Biosafety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company’s website at https://originagritech.com. The Company also maintains an X account to update investors on Company and industry developments, available at https://x.com/origin_agritech.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations concerning the final approval, commercialization, market acceptance, and potential benefits of the three corn varieties described herein, as well as the Company’s variety pipeline, geographic expansion, breeding and biotechnology programs, and strategic goals.
Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions identify forward-looking statements. These statements involve known and unknown risks and uncertainties, including delays in or failure to obtain final regulatory approval, grower adoption of the Company’s varieties, seed production yields and weather conditions, competitive variety introductions, pricing pressure in the Chinese seed market, regulatory and agricultural policy developments in China, and the Company’s ability to fund and execute its plans. These and other factors may cause actual results to differ materially from those expressed or implied by the forward-looking statements.
In particular, the three varieties described in this release have passed preliminary review but remain subject to the public notice period and the subsequent review and final approval requirements under China’s national crop variety approval system. There can be no assurance that final approval, commercialization, market acceptance, or the anticipated market opportunities will occur as currently expected.
Forward-looking statements are not guarantees of future performance. Origin Agritech undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by securities and other applicable laws.
For more information, please contact:
Origin Agritech Limited Contact:
Kate Lang (Mandarin/English) Director of Investor Relations Phone: +86 186-1839-3368 Email: bing.lang@originseed.com.cn
Investor Relations Contact:
Matthew Abenante, IRC President Strategic Investor Relations LLC Tel: 347-947-2093 Email: matthew@strategic-ir.com
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026
IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027
Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027
Company to host conference call and webcast today at 8:00 a.m. ET
NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.
“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Another important piece of Acumen’s value proposition is our Enhanced Brain Delivery™ program, combining a validated blood-brain barrier-penetrating technology with an AβO-selective therapeutic antibody. We continue to make progress on IND-enabling activities in support of a mid-2027 IND submission for a lead candidate and remain encouraged about the potential it holds as a next-generation Alzheimer’s disease treatment.”
Anticipated Milestones
The Company expects to report topline results from ALTITUDE-AD in November 2026.
ALTITUDE-AD is a 3-arm Phase 2 study investigating sabirnetug in 542 participants (N=180 per arm) for the treatment of early Alzheimer’s disease.
ALTITUDE-AD includes two active doses (35 mg/kg, 50 mg/kg, IV Q4W) vs. placebo over an 18-month double-blinded period.
Topline results are expected to include the iADRS (Integrated Alzheimer’s Disease Rating Scale), our primary clinical efficacy endpoint, as well as key secondary endpoints, such as CDR-SB (Clinical Dementia Rating – Sum of the Boxes), certain safety measures such as adverse event rates, including ARIA rates, and key biomarkers.
The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.
Third Quarter 2026 Financial Results
Cash Balance. As of Sept. 30, 2026, cash, cash equivalents and marketable securities totaled $78.6 million compared to cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026. Cash is expected to support current clinical and operational activities into early 2027.
Research and Development (R&D) Expenses. R&D expenses were $21.1 million for the quarter ended Sept. 30, 2026, compared to $22.0 million for the quarter ended Sept. 30, 2025. The decrease was primarily due to reductions in manufacturing and materials costs and CRO costs, which are both associated with our ALTITUDE-AD clinical trial, and partially offset by increased spending for our EBD program.
General and Administrative (G&A) Expenses. G&A expenses were $4.7 million for the quarter ended Sept. 30, 2026, compared to $4.5 million for the quarter ended Sept. 30, 2025.
Loss from Operations. Loss from operations was $25.8 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025. This decrease was due to the decreased R&D expenses over the prior year period.
Net Loss. Net loss was $25.4 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025.
Conference Call Details
Acumen will host a conference call and live audio webcast today, Oct. 26, 2026, at 8:00 a.m. ET.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company’s website at www.acumenpharm.com.
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer’s disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in November 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD®) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, Acumen’s plans to develop a candidate to treat Alzheimer’s Disease utilizing EBD technology, including its expectations with respect to timing for the submission of an IND, the potential of its EBD candidates and the potential for developing a best-in-class therapeutic candidate for people living with Alzheimer’s Disease. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2026 and December 31, 2025
–
–
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 72,327,320 and 60,575,369 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
7
6
Additional paid-in capital
559,914
516,803
Accumulated deficit
(525,286
)
(446,462
)
Accumulated other comprehensive (loss) income
(25
)
83
Total stockholders’ equity
34,610
70,430
Total liabilities and stockholders’ equity
$
85,565
$
122,833
Acumen Pharmaceuticals, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Operating expenses
Research and development
$
21,113
$
21,968
$
65,406
$
84,359
General and administrative
4,700
4,545
14,112
14,274
Total operating expenses
25,813
26,513
79,518
98,633
Loss from operations
(25,813
)
(26,513
)
(79,518
)
(98,633
)
Other income (expense)
Interest income
812
1,639
2,987
6,125
Interest expense
(999
)
(1,068
)
(3,162
)
(3,137
)
Change in fair value of embedded derivatives
650
(440
)
950
(290
)
Other expense, net
(19
)
(69
)
(81
)
(262
)
Total other income
444
62
694
2,436
Net loss
(25,369
)
(26,451
)
(78,824
)
(96,197
)
Other comprehensive gain (loss)
Unrealized (loss) gain on marketable securities
(12
)
86
(108
)
157
Comprehensive loss
$
(25,381
)
$
(26,365
)
$
(78,932
)
$
(96,040
)
Net loss per common share, basic and diluted
$
(0.35
)
$
(0.44
)
$
(1.14
)
$
(1.59
)
Weighted-average shares outstanding, basic and diluted
72,321,459
60,573,425
69,297,155
60,557,668
Acumen Pharmaceuticals, Inc.
Condensed Statements of Cash Flows
(in thousands)
(unaudited)
Nine Months Ended September 30,
2026
2025
Cash flows from operating activities
Net loss
$
(78,824
)
$
(96,197
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
35
46
Stock-based compensation expense
7,626
7,433
Amortization of premiums and accretion of discounts on marketable securities, net
(198
)
(919
)
Change in fair value of embedded derivatives
(950
)
290
Amortization of right-of-use asset
104
93
Realized gain on marketable securities
(6
)
(17
)
Noncash interest expense
1,048
942
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
(1,143
)
1,205
Other long-term assets
11
42
Accounts payable
5,502
(4,966
)
Accrued clinical trial expenses
(2,157
)
(5,460
)
Accrued expenses and other liabilities
96
1,066
Net cash used in operating activities
(68,856
)
(96,442
)
Cash flows from investing activities
Purchases of marketable securities
(40,823
)
(38,056
)
Proceeds from maturities and sales of marketable securities
78,266
145,827
Purchases of property and equipment
–
(88
)
Net cash provided by investing activities
37,443
107,683
Cash flows from financing activities
Proceeds from private placement, net of offering costs
35,441
–
Repayments of debt
(4,987
)
–
Proceeds from exercise of stock options
194
37
Repurchase of common shares to pay employee withholding taxes
(149
)
(73
)
Net cash provided by (used in) financing activities
30,499
(36
)
Net change in cash and cash equivalents and restricted cash
(914
)
11,205
Cash and cash equivalents and restricted cash at the beginning of the period
54,220
35,859
Cash and cash equivalents and restricted cash at the end of the period
Not for distribution to United States newswire services or for dissemination in the United States.
TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that further to the Company’s press releases of September 17, 2026, October 13, 2026, October 20, 2026 and October 21, 2026, LabGold closed, on October 23, 2026, its non-brokered private placement offering, for aggregate gross proceeds of $5,760,115.45.
The non-brokered private placement offering consisted of: 61,326,500 common shares of the Company issued on a non-flow-through basis (the “HD Shares”); and 53,875,809 common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) (the “FT Shares” and, together with the HD Shares, the “Shares”), each at a price of $0.05 per Share, for aggregate gross proceeds of $5,760,115.45 representing the issuance of 115,202,309 Shares (the “Offering”).
The closing of the final tranche of the Offering comprised subscriptions for 61,326,500 HD Shares and 11,200,000 FT Shares and included subscriptions by Matachewan Consolidated Mines, Limited and McChip Resources Inc. (collectively, the “Lead Investors”) for $726,325 of HD Shares, representing 14,526,500 HD Shares.
All securities issued pursuant to the final tranche are subject to a statutory hold period expiring February 24, 2027 in accordance with applicable Canadian securities laws and the policies of the TSXV.
In addition to the statutory hold period expiring February 24, 2027, the HD Shares issued to the Lead Investors are subject to a one-year contractual lock-up, expiring October 23, 2027, subject to customary exceptions. See the Company’s October 20, 2026, press release for more details.
The gross proceeds from the sale of the FT Shares will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures”, as those terms are defined in the Tax Act (the “Qualifying Expenditures”), on the Company’s mineral properties in Canada. The Company will renounce the Qualifying Expenditures in favour of the subscribers of the FT Shares with an effective date no later than the date permitted under the Tax Act, in an aggregate amount not less than the gross proceeds raised from the issuance of the FT Shares. The net proceeds from the sale of the HD Shares will be used for exploration and development activities, working capital and general corporate purposes.
The Offering remains subject to final acceptance of the TSXV. The Company did not pay any finder’s fees in connection with the Offering.
The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable securities laws of any state of the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction.
Five insiders of the Company subscribed for 8,700,000 FT Shares and 17,526,500 HD Shares for an aggregate of $1,311,325 on the closing of the final tranche. The insider private placements are exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company which were issued to the insiders does not exceed 25% of its market capitalization.
About Labrador Gold
Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.
The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects.
The Watson Project, a joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.
The Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.
The Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.
The Company has 286,012,288 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.
For more information, please contact:
Labrador Gold Corp.: Roger Moss, President and CEO
T: 416-704-8291
Website: www.labradorgold.com
X: @LabGoldCorp
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the anticipated use of the proceeds of the Offering; the Company’s intention to incur and renounce Qualifying Expenditures; and the receipt of TSXV approvals.
Forward-looking statements are based on management’s current expectations, estimates, assumptions and beliefs as of the date of this release, including assumptions regarding the satisfaction of the conditions to closing; the availability of applicable prospectus exemptions; the receipt of all required corporate and regulatory approvals, including the acceptance of the TSXV; the availability of Qualifying Expenditures; and the Company’s ability to incur and renounce the Qualifying Expenditures within the periods required under the Tax Act.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, that required corporate or regulatory approvals, including TSXV acceptance, may not be obtained; that sufficient Qualifying Expenditures may not be available; that the Company may not incur or renounce Qualifying Expenditures within the periods required under the Tax Act; and the risks described in the Company’s continuous disclosure filings with Canadian securities regulatory authorities.
Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
